Navigation Links
Ontario Institute for Cancer Research Announces Enhancements to its Intellectual Property Development and Commercialization Program
Date:3/8/2011

TORONTO, March 8, 2011 /PRNewswire/ -- The Ontario Institute for Cancer Research (OICR) announced today it has enhanced its Intellectual Property Development and Commercialization program (IPDC), now called the IPDC Fund. The augmented program is designed to provide broader and deeper support for promising early stage technologies.

"In the face of declining private institutional investment, the new IPDC Fund is designed to offer greater support for the most promising Ontario-based anticancer technologies," said Frank Stonebanks, Vice-President, Commercialization and Chief Commercial Officer of OICR. "It will help bridge the funding gap that too often threatens the development of many early-stage projects."

"Developing intellectual property is key to creating innovative jobs in Ontario," said Glen Murray, Ontario Minister of Research and Innovation. "With the new IPDC fund, OICR is proving it's a world leader both in cancer research and in turning discoveries into viable new technologies on the market."

A common bottleneck in the commercialization of innovative technologies is the scarcity of funding in support of early stage development of inventions. The gap in funding between the traditional public granting agencies and private investors, be they corporate or venture, is often referred to as the developmental "valley of death." OICR's IPDC Fund is designed to overcome this funding gap.

Under the new IPDC Fund, a maximum of $1.5 million will be made available over three years for each eligible project. This represents a substantial increase over the previous program and adds a third year option which was previously unavailable. Additional equity investments are also possible. These enhancements provide OICR the ability to fund compelling assets and technologies and advance them from mid-late stage academic to Series "A" VC-ready investments.

In addition, any Ontario cancer-related intellectual property (IP) is now eligible for funding under the new program, an enhancement over the previous restriction to academic IP sources only.

For more information about the OICR IPDC Fund or to start the application process, please visit the Program's website at: http://www.oicr.on.ca/Commercialization/IPDCP/index.htm. For inquiries concerning licensing any OICR technology, please contact OICR via email at: commercialization@oicr.on.ca.

About OICR

OICR is an innovative cancer research and development institute dedicated to prevention, early detection, diagnosis and treatment of cancer. The Institute is an independent, not-for-profit corporation funded by the Government of Ontario through the Ministry of Research and Innovation. OICR has 500 scientific staff (located at its headquarters and in research institutes and academia across the Province of Ontario) and an $85 million annual operating budget. It has key research efforts underway in small molecules, biologics, stem cells, imaging, genomics, informatics and bio-computing, from early stage research to Phase I clinical trials.

For more information, please visit the website at www.oicr.on.ca/commercialization.


'/>"/>
SOURCE Ontario Institute for Cancer Research (OICR)
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ontario Institute for Cancer Research Validates NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for use in Next Generation Sequencing
2. Koch Institute for Integrative Cancer Research Dedicated Today
3. Sharpest microscope tip lands Canadas Nanotech Institute in Guinness Book of World Records
4. Weizmann Institute scientists used accelerated evolution to develop enzymes that provide protection against nerve gas
5. Polaris Group and The Ludwig Institute for Cancer Research Ltd Initiate Phase 2 Trial of Amino-Acid Degrading Enzyme, ADI-PEG 20, in Patients with Small Cell Lung Cancer
6. Larta Institute NIH Success Stories Featured in 2011 California Biomedical Industry Report
7. Tufts Launches Institute for Biopharmaceutical Partnerships
8. Salk Institute Celebrates Grand Opening of the Waitt Advanced Biophotonics Center
9. Will Rogers Institute Awards Top Doctor $50,000 for Outstanding Contributions to Lung Research
10. Weizmann Institute scientists used accelerated evolution to develop enzymes that provide protection against nerve gas
11. ALS Therapy Development Institute Appoints Anil Godhwani to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 2017  MIODx announced today that it has ... technologies from the University of California, San Francisco ... monitor a patient for response to immune checkpoint ... second license extends the technology with a method ... have an immune-related adverse event (IRAE) from their ...
(Date:2/23/2017)... ... February 23, 2017 , ... Baltimore ... multiple immunoassay-based threat detection technologies by researchers from the Pacific National Northwest ... detection technology was found to have the best level of detection (LOD) ...
(Date:2/23/2017)... Feb. 23, 2017 Aviva Systems Biology ... the acquisition of GenWay Biotech Incorporated, a protein ... and product offering for both the research and ... growth and enhance capabilities for both entities. GenWay,s 18 ... assays will nicely complement ASB,s objective to become ...
(Date:2/22/2017)... ... February 22, 2017 , ... Park Systems , a leader in ... for all SPIE attendees and Park customers on Feb. 27, 2017 from ... San Jose Convention Center. The luncheon will feature a talk on Automated AFM ...
Breaking Biology Technology:
(Date:2/7/2017)... LONG BEACH, New York , February 7, 2017 ... formerly known as ID Global Solutions Corporation [OTC: IDGS], ... identification, identity management and electronic transaction processing services, is ... a reorganization of the Company. Effective January ... Chairman of the Board of Directors, CEO and President. ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
(Date:1/31/2017)... Mass. , Jan. 31, 2017  Spero ... novel therapies for the treatment of bacterial infections, ... set of antibacterial candidates from Pro Bono Bio ... increased prevalence of multi-drug resistant forms of Gram-negative ... Cantab Anti Infectives Ltd, a PBB group company. ...
Breaking Biology News(10 mins):